Total Payments
$28,726
2024 Payments
$18,659
Companies
6
Transactions
18
Medicare Patients
694
Medicare Billing
$79,882
Payment Breakdown by Category
Travel$10,255 (35.7%)
Consulting$6,474 (22.5%)
Research$5,838 (20.3%)
Other$5,464 (19.0%)
Food & Beverage$694.92 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $10,255 | 5 | 35.7% |
| Consulting Fee | $6,474 | 2 | 22.5% |
| Unspecified | $5,838 | 2 | 20.3% |
| Honoraria | $5,464 | 1 | 19.0% |
| Food and Beverage | $694.92 | 8 | 2.4% |
Payments by Type
General
$22,888
16 transactions
Research
$5,838
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacosmos Therapeutics Inc. | $15,125 | 4 | $0 (2024) |
| Celgene Corporation | $5,838 | 2 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $4,038 | 6 | $0 (2023) |
| GENZYME CORPORATION | $3,674 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29.80 | 1 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $21.33 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,659 | 7 | Pharmacosmos Therapeutics Inc. ($15,125) |
| 2023 | $81.25 | 3 | GENZYME CORPORATION ($44.71) |
| 2022 | $124.29 | 1 | GENZYME CORPORATION ($124.29) |
| 2018 | $8,541 | 6 | Celgene Corporation ($4,518) |
| 2017 | $1,320 | 1 | Celgene Corporation ($1,320) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Honoraria | In-kind items and services | $5,464.00 | General |
| Category: HEMATOLOGY | ||||||
| 10/31/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $198.88 | General |
| Category: HEMATOLOGY | ||||||
| 10/07/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $125.85 | General |
| Category: HEMATOLOGY | ||||||
| 08/12/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $9,335.80 | General |
| Category: HEMATOLOGY | ||||||
| 05/14/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,324.00 | General |
| 05/14/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $180.73 | General |
| 03/15/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.80 | General |
| Category: Immunology | ||||||
| 12/10/2023 | GENZYME CORPORATION | CABLIVI (Biological), ENJAYMO | Food and Beverage | In-kind items and services | $44.71 | General |
| Category: Hematology | ||||||
| 12/10/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $21.33 | General |
| Category: Hematology | ||||||
| 08/30/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Rare Disease | ||||||
| 11/03/2022 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $124.29 | General |
| 08/03/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: Immunology | ||||||
| 08/03/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Travel and Lodging | Cash or cash equivalent | $93.88 | General |
| Category: Immunology | ||||||
| 07/14/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $153.00 | General |
| Category: Immunology | ||||||
| 07/13/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Travel and Lodging | In-kind items and services | $342.39 | General |
| Category: Immunology | ||||||
| 07/13/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Travel and Lodging | In-kind items and services | $283.84 | General |
| Category: Immunology | ||||||
| 02/02/2018 | Celgene Corporation | Sotatercept (Drug) | — | Cash or cash equivalent | $4,518.00 | Research |
| Study: ACE-011-MDS-001 - An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-p | ||||||
| 05/16/2017 | Celgene Corporation | Sotatercept (Drug) | — | Cash or cash equivalent | $1,320.00 | Research |
| Study: ACE-011-MDS-001 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACE-011-MDS-001 - An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-p | Celgene Corporation | $4,518 | 1 |
| ACE-011-MDS-001 | Celgene Corporation | $1,320 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 215 | 270 | $98,330 | $23,312 |
| 2022 | 4 | 146 | 214 | $33,396 | $14,046 |
| 2021 | 7 | 160 | 260 | $45,777 | $19,747 |
| 2020 | 7 | 173 | 381 | $59,120 | $22,777 |
Total Patients
694
Total Services
1,125
Medicare Billing
$79,882
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 66 | 66 | $34,320 | $7,507 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 45 | 68 | $13,600 | $4,023 | 29.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 26 | $14,040 | $3,099 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $14,040 | $2,916 | 20.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 37 | $11,100 | $2,670 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 30 | $6,270 | $1,675 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 16 | $4,960 | $1,421 | 28.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 63 | 92 | $10,128 | $4,590 | 45.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 60 | $9,900 | $4,487 | 45.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $7,758 | $2,864 | 36.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 34 | $5,610 | $2,106 | 37.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 65 | $10,505 | $5,126 | 48.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 50 | 91 | $9,937 | $4,508 | 45.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 38 | $6,090 | $2,549 | 41.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $5,985 | $2,190 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 19 | $5,051 | $2,160 | 42.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $4,519 | $1,780 | 39.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 12 | $3,690 | $1,435 | 38.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 29 | 139 | $21,320 | $8,449 | 39.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 45 | 137 | $13,977 | $5,503 | 39.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 41 | 41 | $10,317 | $3,775 | 36.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 14 | $4,194 | $1,563 | 37.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 18 | 18 | $3,863 | $1,473 | 38.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 21 | $3,758 | $1,349 | 35.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 11 | $1,691 | $665.35 | 39.3% |
About Dr. Johnson Liu, MD
Dr. Johnson Liu, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861552903.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Johnson Liu, MD has received a total of $28,726 in payments from pharmaceutical and medical device companies, with $18,659 received in 2024. These payments were reported across 18 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($10,255).
As a Medicare-enrolled provider, Liu has provided services to 694 Medicare beneficiaries, totaling 1,125 services with total Medicare billing of $79,882. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 12/11/2006
- Last Updated 11/07/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1861552903
Products in Payments
- MONOFERRIC (Drug) $15,125
- Sotatercept (Drug) $5,838
- SOLIRIS (Drug) $4,023
- CABLIVI (Biological) $44.71
- Fabhalta (Drug) $29.80
- Empaveli (Drug) $21.33
- ULTOMIRIS (Biological) $15.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205